The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
BeOne Medicines Ltd. price-fcf ratio for the quarter ending 2026-06-30 was 314.96, a 77.68% decline year-over-year.
BeOne Medicines Ltd. price-fcf ratio for the quarter ending 2026-03-31 was 384.71, a change of 2,501.04 year-over-year.
BeOne Medicines Ltd. price-fcf ratio for the quarter ending 2025-12-31 was 464.94, a change of 869.58 year-over-year.
BeOne Medicines Ltd. price-fcf ratio for the quarter ending 2025-09-30 was 900.04, a change of 1,212.91 year-over-year.
BeOne Medicines Ltd. price-fcf ratio for fiscal 2026 was 314.96.
BeOne Medicines Ltd. price-fcf ratio for fiscal 2025 was 464.94, a change of 869.58 from fiscal 2024.
BeOne Medicines Ltd. price-fcf ratio for fiscal 2024 was -404.65, a change of -262.03 from fiscal 2023.
BeOne Medicines Ltd. price-fcf ratio for fiscal 2023 was -142.61, a change of 21.09 from fiscal 2022.